Charles River Laboratories International (CRL) Common Equity (2009 - 2026)

Charles River Laboratories International's Common Equity history runs 17 years deep, the most recent figure standing at $3.2 billion for Q4 2025.

• In Q4 2025, Common Equity fell 8.57% year-over-year to $3.2 billion; the TTM figure through Dec 2025 stood at $3.2 billion (down 8.57% YoY), while the FY2025 annual figure was $3.2 billion, down 8.57% from the prior year.
• Common Equity for Q4 2025 stood at $3.2 billion, down from $3.4 billion in the prior quarter.
• The five-year high for Common Equity was $3.8 billion in Q3 2024, with the low at $2.2 billion in Q1 2021.
• The 5-year median for Common Equity is $3.2 billion (2025), against an average of $3.1 billion.
• The sharpest annual moves came in 2021 and 2025: Common Equity soared 32.25% in 2021, then dropped 12.23% in 2025.
• Charles River Laboratories International's Common Equity stood at $2.5 billion in 2021, then gained by 17.41% to $3.0 billion in 2022, then advanced by 20.84% to $3.6 billion in 2023, then declined by 3.76% to $3.5 billion in 2024, then decreased by 8.57% to $3.2 billion in 2025.
• Business Quant data shows CRL's Common Equity at $3.2 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.4 billion in Q2 2025.